
Authors: Hunter Moseley
Grants: None Found
Abstract: None
Conclusions: None
Copyrights: None
DOI: None
Journal: None
Keywords: None
Methods: None
PMID: None
Results: None
Title: Plk1 phosphorylation of PHGDH to regulate serine metabolism
PMCID: None
Publication Year: 2023
Publication Month: None
Publication Day: None
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Moseley, Hunter
Last Author: Moseley, Hunter
Pub_Authors: 
Moseley, Hunter None kentucky
References: None

Authors: Justin F Creeden, Zachary A Kipp, Mei Xu, Robert M Flight, Hunter N B Moseley, Genesee J Martinez, Wang-Hsin Lee, Khaled Alganem, Ali S Imami, Megan R McMullen, Sanjoy Roychowdhury, Atta M Nawabi, Jennifer A Hipp, Samir Softic, Steven A Weinman, Robert McCullumsmith, Laura E Nagy, Terry D Hinds
Grants: R01 MH121102, R01 AG057598, R01 DK121797, R01 MH107487, P30 CA177558, P50 AA024333
Abstract: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks.
We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Conclusions: None
Copyrights: © 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
DOI: 10.1002/hep.32467
Journal: Hepatology (Baltimore, Md.)
Keywords: []
Methods: None
PMID: 35313030
Results: None
Title: Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.
PMCID: PMC9489820
Publication Year: 2022
Publication Month: 3
Publication Day: 22
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Creeden, Justin F
Last Author: Hinds, Terry D
Pub_Authors: 
Creeden, Justin F JF Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Kipp, Zachary A ZA Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Xu, Mei M Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Flight, Robert M RM Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Moseley, Hunter N B HNB Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Center for Clinical and Translational Science, University of Kentucky, Lexington, Kentucky, USA.
Martinez, Genesee J GJ Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lee, Wang-Hsin WH Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Alganem, Khaled K Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Imami, Ali S AS Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
McMullen, Megan R MR Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Roychowdhury, Sanjoy S Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Nawabi, Atta M AM Division of Transplant and Hepatobiliary, Department of Surgery, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Hipp, Jennifer A JA Strata Oncology, Ann Arbor, Michigan, USA.
Softic, Samir S Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Department of Pediatrics, University of Kentucky, Lexington, Kentucky, USA.
Weinman, Steven A SA Department of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
McCullumsmith, Robert R Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Neurosciences Institute, ProMedica, Toledo, Ohio, USA.
Nagy, Laura E LE Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Gastroenterology and Hepatology, Center for Liver Disease Research, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Hinds, Terry D TD Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
References: 
Citation: Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Schuppan D, Ashfaq‐Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68–69:435–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Eslam M, Sanyal AJ, George J, International Consensus P . MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 e1991.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Hipp JA, Hong S, Mitchell ZL, Franco NR, et al. Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet‐induced obesity. Am J Physiol Regul Integr Comp Physiol. 2019;317:R733–R745.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. Bilirubin nanoparticles reduce diet‐induced hepatic steatosis, improve fat utilization, and increase plasma beta‐hydroxybutyrate. Front Pharmacol. 2020;11:594574.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Hinds TD Jr. Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:9493.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hamoud AR, Weaver L, Stec DE, Hinds TD Jr. Bilirubin in the liver‐gut signaling axis. Trends Endocrinol Metab. 2018;29:140–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Hosick PA, Hankins MW, Nestor‐Kalinoski A, Stec DE. Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha. Am J Physiol Endocrinol Metab. 2017;312:E244–E252.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD, Sodhi K, Meadows C, Fedorova L, Puri N, Kim DH, et al. Increased HO‐1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring). 2014;22:705–12.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Weaver L, Hamoud AR, Stec DE, Hinds TD Jr. Biliverdin reductase and bilirubin in hepatic disease. Am J Physiol Gastrointest Liver Physiol. 2018;314:G668–G676.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med. 2005;117:237–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pritchard MT, Nagy LE. Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr‐1‐deficient mice. Am J Pathol. 2010;176:2743–52.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Frangogiannis N. Transforming growth factor‐beta in tissue fibrosis. J Exp Med. 2020;217:e20190103.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6‐EGFR‐induced Kupffer cells secrete TGF‐beta1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C‐MYC/EZH2 pathway in liver fibrosis. J Cell Mol Med. 2018;22:5050–61.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Li H‐G, You P‐T, Xia YU, Cai YU, Tu Y‐J, Wang M‐H, et al. Yu Gan long ameliorates hepatic fibrosis by inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 signaling pathways in CCl4‐induced liver fibrosis rats. Curr Med Sci. 2020;40:539–47.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Carpino G, Morini S, Ginannicorradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha‐SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349–56.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014;34:185–92.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Moll S, Desmoulière A, Moeller MJ, Pache J‐C, Badi L, Arcadu F, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta Mol Cell Res. 2019;1866:118474.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu S‐H, et al. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int J Mol Sci. 2020;21:8823.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Svegliati‐Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Peterson SW, Angelico M, Masella R, Foster K, Gandin C, Cantafora A. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients. Ital J Gastroenterol. 1992;24:65–71.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Okada Y. Increased insulin binding to erythrocytes in chronic liver disease. Acta Med Okayama. 1981;35:155–64.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Petrides AS, Passlack W, Reinauer H, Stremmel W, Strohmeyer G. Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis. Klin Wochenschr. 1987;65:873–8.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Teng CS, Ho PW, Yeung RT. Down‐regulation of insulin receptors in postnecrotic cirrhosis of liver. J Clin Endocrinol Metab. 1982;55:524–30.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Greco AV, Bertoli A, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG. Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes. Horm Metab Res. 1980;12:577–81.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Harewood MS, Proietto J, Dudley F, Alford FP. Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes. Metabolism. 1982;31:1241–6.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484–95.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yen FS, Lai JN, Wei JC, Chiu LT, Hsu CC, Hou MC, et al. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis? BMC Gastroenterol. 2021;21:263.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Meroni M, Baselli G, Bassani G, Rametta R, Pietrelli A, et al. Insulin resistance promotes Lysyl oxidase like 2 induction and fibrosis accumulation in non‐alcoholic fatty liver disease. Clin Sci (Lond). 2017;131:1301–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non‐alcoholic fatty liver disease. Gut. 2010;59:267–73.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr. Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem. 2014;289:17885–94.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Smedlund KB, Sanchez ER, Hinds TD Jr. FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol Metab. 2021;32:862–74.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Nestor‐Kalinoski AL, Donald MC, Mitchell ZL, Creeden JF, et al. Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice. Biomolecules. 2020;10:387.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Burns KA, Hosick PA, McBeth L, Nestor‐Kalinoski A, Drummond HA, et al. Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator‐activated receptor (PPAR) alpha. J Biol Chem. 2016;291:25179–91.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: O'Brien L, Hosick PA, John K, Stec DE, Hinds TD Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab. 2015;26:212–20.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai CX, Buddha H, Castelino‐Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of insulin‐PI3K/Akt‐p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci. 2017;62:968–78.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zhang F, Zhang Z, Kong D, Zhang X, Chen LI, Zhu X, et al. Tetramethylpyrazine reduces glucose and insulin‐induced activation of hepatic stellate cells by inhibiting insulin receptor‐mediated PI3K/AKT and ERK pathways. Mol Cell Endocrinol. 2014;382:197–204.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Mateus T, Martins F, Nunes A, Herdeiro MT, Rebelo S. Metabolic alterations in myotonic dystrophy type 1 and their correlation with lipin. Int J Environ Res Public Health. 2021;18:1794.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, et al. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One. 2007;2:e1134.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Bhardwaj RR, Duchini A. Non‐alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep Gastroenterol. 2010;4:100–3.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yang J, Zhang X, Yi L, Yang L, Wang WE, Zeng C, et al. Hepatic PKA inhibition accelerates the lipid accumulation in liver. Nutr Metab (Lond). 2019;16:69.
Title: None
PMID: None
PMCID: None
DOI: None


Authors: Sweta Ojha, P Travis Thompson, Christian D Powell, Hunter N B Moseley, Kelly G Pennell
Grants: P42 ES007380, 2020026
Abstract: Exposure to per- and polyfluoroalkyl substances (PFAS) in drinking water is widely recognized as a public health concern. Decision-makers who are responsible for managing PFAS drinking water risks lack the tools to acquire the information they need. In response to this need, we provide a detailed description of a Kentucky dataset that allows decision-makers to visualize potential hot-spot areas and evaluate drinking water systems that may be susceptible to PFAS contamination. The dataset includes information extracted from publicly available sources to create five different maps in ArcGIS Online and highlights potential sources of PFAS contamination in the environment in relation to drinking water systems. As datasets of PFAS drinking water sampling continue to grow as part of evolving regulatory requirements, we used this Kentucky dataset as an example to promote the reuse of this dataset and others like it. We incorporated the FAIR (Findable, Accessible, Interoperable, and Reusable) principles by creating a Figshare item that includes all data and associated metadata with these five ArcGIS maps.
Conclusions: None
Copyrights: © 2023. The Author(s).
DOI: 10.1038/s41597-023-02277-x
Journal: Scientific data
Keywords: []
Methods: None
PMID: 37328532
Results: None
Title: Identifying and sharing per-and polyfluoroalkyl substances hot-spot areas and exposures in drinking water.
PMCID: PMC10275912
Publication Year: 2023
Publication Month: 6
Publication Day: 17
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Ojha, Sweta
Last Author: Pennell, Kelly G
Pub_Authors: 
Ojha, Sweta S University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Thompson, P Travis PT University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Powell, Christian D CD University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Computer Science (Data Science Program), Lexington, Kentucky, USA.
Moseley, Hunter N B HNB University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington, Kentucky, USA.
Pennell, Kelly G KG University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA. kellypennell@uky.edu.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA. kellypennell@uky.edu.
References: 
Citation: Environmental Protection Agency (EPA), PFAS Strategic Roadmap: EPA’s Commitments to Action 2021–2024. https://www.epa.gov/system/files/documents/2021-10/pfas-roadmap_final-508.pdf (2021).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Da Silva BF, Ahmadireskety A, Aristizabal-Henao JJ, Bowden JA. A rapid and simple method to quantify per-and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates. MethodsX. 2020;7:101111–10111. doi: 10.1016/j.mex.2020.101111.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.mex.2020.101111

Citation: Hagstrom AL, et al. Yale School of Public Health Symposium: an overview of the challenges and opportunities associated with per-and polyfluoroalkyl substances (PFAS) Sci. Total Envir. 2021;778:146192. doi: 10.1016/j.scitotenv.2021.146192.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2021.146192

Citation: Groffen T, et al. A rapid method for the detection and quantification of legacy and emerging per-and polyfluoroalkyl substances (PFAS) in bird feathers using UPLC-MS/MS. J. Chromatogr. B. 2021;1172:122653. doi: 10.1016/j.jchromb.2021.122653.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jchromb.2021.122653

Citation: Glüge J, et al. An overview of the uses of per-and polyfluoroalkyl substances (PFAS) Envir. Sci.-Proc. Imp. 2020;22:2345–2373.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Rogers RD, Reh CM, Breysse P. Advancing per-and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations. J. Exp. Sci. Envir. Epi. 2021;31:961–971. doi: 10.1038/s41370-021-00316-6.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41370-021-00316-6

Citation: Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per-and polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea food web. Envir. Poll. 2007;148:360–371. doi: 10.1016/j.envpol.2006.09.021.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2006.09.021

Citation: Fenton SE, et al. Per‐and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Envir. Tox. Chem. 2021;40:606–630. doi: 10.1002/etc.4890.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4890

Citation: Kucharzyk KH, Darlington R, Benotti M, Deeb R, Hawley E. Novel treatment technologies for PFAS compounds: A critical review. J. Environ. Manage. 2017;204:757–764. doi: 10.1016/j.jenvman.2017.08.016.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jenvman.2017.08.016

Citation: National Academies of Sciences, Engineering, and Medicine (NASEM), Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. 10.17226/26156 (2022).
Title: None
PMID: None
PMCID: None
DOI: 10.17226/26156

Citation: Rahman MF, Peldszus S, Anderson WB. Behaviour and fate of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in drinking water treatment: A review. Water Res. 2014;50:318–340. doi: 10.1016/j.watres.2013.10.045.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2013.10.045

Citation: De Silva AO, et al. PFAS exposure pathways for humans and wildlife: a synthesis of current knowledge and key gaps in understanding. Environ. Tox. Chem. 2021;40:631–657. doi: 10.1002/etc.4935.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4935

Citation: Olsen GW, et al. Per-and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000–2015. Environ. Res. 2017;157:87–95. doi: 10.1016/j.envres.2017.05.013.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2017.05.013

Citation: Domingo JL, Nadal M. Human exposure to per-and polyfluoroalkyl substances (PFAS) through drinking water: a review of the recent scientific literature. Environ. Res. 2019;177:108648–108648. doi: 10.1016/j.envres.2019.108648.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2019.108648

Citation: Hepburn E, et al. Contamination of groundwater with per-and polyfluoroalkyl substances (PFAS) from legacy landfills in an urban re-development precinct. Environ. Poll. 2019;248:101–113. doi: 10.1016/j.envpol.2019.02.018.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2019.02.018

Citation: Bai X, Son Y. Perfluoroalkyl substances (PFAS) in surface water and sediments from two urban watersheds in Nevada, USA. Sci. Tot. Envir. 2021;751:141622–141622. doi: 10.1016/j.scitotenv.2020.141622.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2020.141622

Citation: Li Y, et al. Formation and fate of perfluoroalkyl acids (PFAAs) in a laboratory-scale urban wastewater system. Water Res. 2022;216:118295–118295. doi: 10.1016/j.watres.2022.118295.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2022.118295

Citation: Hale SE, et al. Sorbent amendment as a remediation strategy to reduce PFAS mobility and leaching in a contaminated sandy soil from a Norwegian firefighting training facility. Chemosphere. 2017;171:9–18. doi: 10.1016/j.chemosphere.2016.12.057.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2016.12.057

Citation: Barber JL, et al. Analysis of per-and polyfluorinated alkyl substances in air samples from Northwest Europe. J. Environ. Monit. 2007;9:530–541. doi: 10.1039/b701417a.
Title: None
PMID: None
PMCID: None
DOI: 10.1039/b701417a

Citation: Koch A, et al. Point source characterization of per-and polyfluoroalkyl substances (PFASs) and extractable organofluorine (EOF) in freshwater and aquatic invertebrates. Environ. Sci.-Proc. Imp. 2019;21:1887–1898.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pétré MA, et al. Per-and polyfluoroalkyl substance (PFAS) transport from groundwater to streams near a PFAS manufacturing facility in North Carolina, USA. Environ. Sci. Tech. 2021;55:5848–5856. doi: 10.1021/acs.est.0c07978.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c07978

Citation: Ahrens L, Norström K, Viktor T, Cousins AP, Josefsson S. Stockholm Arlanda Airport as a source of per-and polyfluoroalkyl substances to water, sediment and fish. Chemosphere. 2015;129:33–38. doi: 10.1016/j.chemosphere.2014.03.136.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2014.03.136

Citation: Adamson DT, et al. Mass-based, field-scale demonstration of PFAS retention within AFFF-associated source areas. Environ. Sci. Tech. 2020;54:15768–15777. doi: 10.1021/acs.est.0c04472.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c04472

Citation: Quinnan J, et al. Application of PFAS‐mobile lab to support adaptive characterization and flux‐based conceptual site models at AFFF releases. Remed. J. 2021;31:7–26. doi: 10.1002/rem.21680.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/rem.21680

Citation: Schroeder T, Bond D, Foley J. PFAS soil and groundwater contamination via industrial airborne emission and land deposition in SW Vermont and Eastern New York State, USA. Environ. Sci.-Proc. Imp. 2021;23:291–301.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hale SE, Canivet B, Rundberget T, Langberg HA, Allan IJ. Using passive samplers to track Per and Polyfluoroalkyl Substances (PFAS) emissions from the paper industry: laboratory calibration and field verification. Front. Env. Sci. 2021;9:621–629. doi: 10.3389/fenvs.2021.796026.
Title: None
PMID: None
PMCID: None
DOI: 10.3389/fenvs.2021.796026

Citation: Hu XC, et al. Detection of poly-and perfluoroalkyl substances (PFASs) in US drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. Environ. Sci. Tech. Let. 2016;3:344–350. doi: 10.1021/acs.estlett.6b00260.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.estlett.6b00260

Citation: Ojha S, et al. A geospatial and binomial logistic regression model to prioritize sampling for per‐and polyfluorinated alkyl substances in public water systems. Integr. Environ. Assess. 2023;19:163–174. doi: 10.1002/ieam.4614.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/ieam.4614

Citation: Ebert JC, Altman RB. Robust recognition of zinc binding sites in proteins. Protein Sci. 2008;17:54–65. doi: 10.1110/ps.073138508.
Title: None
PMID: None
PMCID: None
DOI: 10.1110/ps.073138508

Citation: Wilkinson MD, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data. 2016;3:1–9. doi: 10.1038/sdata.2016.18.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/sdata.2016.18

Citation: Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur. J. Hum. Genet. 2018;26:931–936. doi: 10.1038/s41431-018-0160-0.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41431-018-0160-0

Citation: Thompson P. T., Ojha S., Powell C. D., Pennell K. G. & Moseley H. N. B. A proposed FAIR approach for disseminating geospatial information system maps. Accepted Sci. Data (2023).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zsóka Á, Szerényi ZM, Széchy A, Kocsis T. Greening due to environmental education? Environmental knowledge, attitudes, consumer behavior and everyday pro-environmental activities of Hungarian high school and university students. J. Clean. Prod. 2013;48:126–138. doi: 10.1016/j.jclepro.2012.11.030.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jclepro.2012.11.030

Citation: Guelfo JL, Adamson DT. Evaluation of a national data set for insights into sources, composition, and concentrations of per-and polyfluoroalkyl substances (PFASs) in US drinking water. Environ, Poll. 2018;236:505–513. doi: 10.1016/j.envpol.2018.01.066.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2018.01.066

Citation: Ohja S, Thompson PT, Powell CD, Moselet HNB, Pennell KP. 2022. A FAIR approach to detect and share PFAS hot-spot areas and water systems in Kentucky. Figshare.
Title: None
PMID: None
PMCID: None
DOI: 10.6084/m9.figshare.15218958


Authors: Hunter Moseley
Grants: None Found
Abstract: None
Conclusions: None
Copyrights: None
DOI: None
Journal: None
Keywords: None
Methods: None
PMID: None
Results: None
Title: Plk1 phosphorylation of PHGDH to regulate serine metabolism
PMCID: None
Publication Year: 2023
Publication Month: None
Publication Day: None
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Moseley, Hunter
Last Author: Moseley, Hunter
Pub_Authors: 
Moseley, Hunter None kentucky
References: None

Authors: Justin F Creeden, Zachary A Kipp, Mei Xu, Robert M Flight, Hunter N B Moseley, Genesee J Martinez, Wang-Hsin Lee, Khaled Alganem, Ali S Imami, Megan R McMullen, Sanjoy Roychowdhury, Atta M Nawabi, Jennifer A Hipp, Samir Softic, Steven A Weinman, Robert McCullumsmith, Laura E Nagy, Terry D Hinds
Grants: R01 MH121102, R01 AG057598, R01 DK121797, R01 MH107487, P30 CA177558, P50 AA024333
Abstract: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks.
We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Conclusions: None
Copyrights: © 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
DOI: 10.1002/hep.32467
Journal: Hepatology (Baltimore, Md.)
Keywords: []
Methods: None
PMID: 35313030
Results: None
Title: Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.
PMCID: PMC9489820
Publication Year: 2022
Publication Month: 3
Publication Day: 22
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Creeden, Justin F
Last Author: Hinds, Terry D
Pub_Authors: 
Creeden, Justin F JF Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Kipp, Zachary A ZA Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Xu, Mei M Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Flight, Robert M RM Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Moseley, Hunter N B HNB Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Center for Clinical and Translational Science, University of Kentucky, Lexington, Kentucky, USA.
Martinez, Genesee J GJ Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lee, Wang-Hsin WH Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Alganem, Khaled K Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Imami, Ali S AS Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
McMullen, Megan R MR Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Roychowdhury, Sanjoy S Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Nawabi, Atta M AM Division of Transplant and Hepatobiliary, Department of Surgery, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Hipp, Jennifer A JA Strata Oncology, Ann Arbor, Michigan, USA.
Softic, Samir S Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Department of Pediatrics, University of Kentucky, Lexington, Kentucky, USA.
Weinman, Steven A SA Department of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
McCullumsmith, Robert R Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Neurosciences Institute, ProMedica, Toledo, Ohio, USA.
Nagy, Laura E LE Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Gastroenterology and Hepatology, Center for Liver Disease Research, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Hinds, Terry D TD Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
References: 
Citation: Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Schuppan D, Ashfaq‐Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68–69:435–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Eslam M, Sanyal AJ, George J, International Consensus P . MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 e1991.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Hipp JA, Hong S, Mitchell ZL, Franco NR, et al. Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet‐induced obesity. Am J Physiol Regul Integr Comp Physiol. 2019;317:R733–R745.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. Bilirubin nanoparticles reduce diet‐induced hepatic steatosis, improve fat utilization, and increase plasma beta‐hydroxybutyrate. Front Pharmacol. 2020;11:594574.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Hinds TD Jr. Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:9493.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hamoud AR, Weaver L, Stec DE, Hinds TD Jr. Bilirubin in the liver‐gut signaling axis. Trends Endocrinol Metab. 2018;29:140–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Hosick PA, Hankins MW, Nestor‐Kalinoski A, Stec DE. Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha. Am J Physiol Endocrinol Metab. 2017;312:E244–E252.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD, Sodhi K, Meadows C, Fedorova L, Puri N, Kim DH, et al. Increased HO‐1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring). 2014;22:705–12.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Weaver L, Hamoud AR, Stec DE, Hinds TD Jr. Biliverdin reductase and bilirubin in hepatic disease. Am J Physiol Gastrointest Liver Physiol. 2018;314:G668–G676.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med. 2005;117:237–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pritchard MT, Nagy LE. Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr‐1‐deficient mice. Am J Pathol. 2010;176:2743–52.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Frangogiannis N. Transforming growth factor‐beta in tissue fibrosis. J Exp Med. 2020;217:e20190103.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6‐EGFR‐induced Kupffer cells secrete TGF‐beta1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C‐MYC/EZH2 pathway in liver fibrosis. J Cell Mol Med. 2018;22:5050–61.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Li H‐G, You P‐T, Xia YU, Cai YU, Tu Y‐J, Wang M‐H, et al. Yu Gan long ameliorates hepatic fibrosis by inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 signaling pathways in CCl4‐induced liver fibrosis rats. Curr Med Sci. 2020;40:539–47.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Carpino G, Morini S, Ginannicorradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha‐SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349–56.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014;34:185–92.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Moll S, Desmoulière A, Moeller MJ, Pache J‐C, Badi L, Arcadu F, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta Mol Cell Res. 2019;1866:118474.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu S‐H, et al. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int J Mol Sci. 2020;21:8823.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Svegliati‐Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Peterson SW, Angelico M, Masella R, Foster K, Gandin C, Cantafora A. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients. Ital J Gastroenterol. 1992;24:65–71.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Okada Y. Increased insulin binding to erythrocytes in chronic liver disease. Acta Med Okayama. 1981;35:155–64.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Petrides AS, Passlack W, Reinauer H, Stremmel W, Strohmeyer G. Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis. Klin Wochenschr. 1987;65:873–8.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Teng CS, Ho PW, Yeung RT. Down‐regulation of insulin receptors in postnecrotic cirrhosis of liver. J Clin Endocrinol Metab. 1982;55:524–30.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Greco AV, Bertoli A, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG. Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes. Horm Metab Res. 1980;12:577–81.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Harewood MS, Proietto J, Dudley F, Alford FP. Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes. Metabolism. 1982;31:1241–6.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484–95.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yen FS, Lai JN, Wei JC, Chiu LT, Hsu CC, Hou MC, et al. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis? BMC Gastroenterol. 2021;21:263.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Meroni M, Baselli G, Bassani G, Rametta R, Pietrelli A, et al. Insulin resistance promotes Lysyl oxidase like 2 induction and fibrosis accumulation in non‐alcoholic fatty liver disease. Clin Sci (Lond). 2017;131:1301–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non‐alcoholic fatty liver disease. Gut. 2010;59:267–73.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr. Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem. 2014;289:17885–94.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Smedlund KB, Sanchez ER, Hinds TD Jr. FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol Metab. 2021;32:862–74.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Nestor‐Kalinoski AL, Donald MC, Mitchell ZL, Creeden JF, et al. Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice. Biomolecules. 2020;10:387.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Burns KA, Hosick PA, McBeth L, Nestor‐Kalinoski A, Drummond HA, et al. Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator‐activated receptor (PPAR) alpha. J Biol Chem. 2016;291:25179–91.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: O'Brien L, Hosick PA, John K, Stec DE, Hinds TD Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab. 2015;26:212–20.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai CX, Buddha H, Castelino‐Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of insulin‐PI3K/Akt‐p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci. 2017;62:968–78.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zhang F, Zhang Z, Kong D, Zhang X, Chen LI, Zhu X, et al. Tetramethylpyrazine reduces glucose and insulin‐induced activation of hepatic stellate cells by inhibiting insulin receptor‐mediated PI3K/AKT and ERK pathways. Mol Cell Endocrinol. 2014;382:197–204.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Mateus T, Martins F, Nunes A, Herdeiro MT, Rebelo S. Metabolic alterations in myotonic dystrophy type 1 and their correlation with lipin. Int J Environ Res Public Health. 2021;18:1794.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, et al. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One. 2007;2:e1134.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Bhardwaj RR, Duchini A. Non‐alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep Gastroenterol. 2010;4:100–3.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yang J, Zhang X, Yi L, Yang L, Wang WE, Zeng C, et al. Hepatic PKA inhibition accelerates the lipid accumulation in liver. Nutr Metab (Lond). 2019;16:69.
Title: None
PMID: None
PMCID: None
DOI: None


Authors: Sweta Ojha, P Travis Thompson, Christian D Powell, Hunter N B Moseley, Kelly G Pennell
Grants: P42 ES007380, 2020026
Abstract: Exposure to per- and polyfluoroalkyl substances (PFAS) in drinking water is widely recognized as a public health concern. Decision-makers who are responsible for managing PFAS drinking water risks lack the tools to acquire the information they need. In response to this need, we provide a detailed description of a Kentucky dataset that allows decision-makers to visualize potential hot-spot areas and evaluate drinking water systems that may be susceptible to PFAS contamination. The dataset includes information extracted from publicly available sources to create five different maps in ArcGIS Online and highlights potential sources of PFAS contamination in the environment in relation to drinking water systems. As datasets of PFAS drinking water sampling continue to grow as part of evolving regulatory requirements, we used this Kentucky dataset as an example to promote the reuse of this dataset and others like it. We incorporated the FAIR (Findable, Accessible, Interoperable, and Reusable) principles by creating a Figshare item that includes all data and associated metadata with these five ArcGIS maps.
Conclusions: None
Copyrights: © 2023. The Author(s).
DOI: 10.1038/s41597-023-02277-x
Journal: Scientific data
Keywords: []
Methods: None
PMID: 37328532
Results: None
Title: Identifying and sharing per-and polyfluoroalkyl substances hot-spot areas and exposures in drinking water.
PMCID: PMC10275912
Publication Year: 2023
Publication Month: 6
Publication Day: 17
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Ojha, Sweta
Last Author: Pennell, Kelly G
Pub_Authors: 
Ojha, Sweta S University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Thompson, P Travis PT University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Powell, Christian D CD University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Computer Science (Data Science Program), Lexington, Kentucky, USA.
Moseley, Hunter N B HNB University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington, Kentucky, USA.
Pennell, Kelly G KG University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA. kellypennell@uky.edu.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA. kellypennell@uky.edu.
References: 
Citation: Environmental Protection Agency (EPA), PFAS Strategic Roadmap: EPA’s Commitments to Action 2021–2024. https://www.epa.gov/system/files/documents/2021-10/pfas-roadmap_final-508.pdf (2021).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Da Silva BF, Ahmadireskety A, Aristizabal-Henao JJ, Bowden JA. A rapid and simple method to quantify per-and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates. MethodsX. 2020;7:101111–10111. doi: 10.1016/j.mex.2020.101111.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.mex.2020.101111

Citation: Hagstrom AL, et al. Yale School of Public Health Symposium: an overview of the challenges and opportunities associated with per-and polyfluoroalkyl substances (PFAS) Sci. Total Envir. 2021;778:146192. doi: 10.1016/j.scitotenv.2021.146192.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2021.146192

Citation: Groffen T, et al. A rapid method for the detection and quantification of legacy and emerging per-and polyfluoroalkyl substances (PFAS) in bird feathers using UPLC-MS/MS. J. Chromatogr. B. 2021;1172:122653. doi: 10.1016/j.jchromb.2021.122653.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jchromb.2021.122653

Citation: Glüge J, et al. An overview of the uses of per-and polyfluoroalkyl substances (PFAS) Envir. Sci.-Proc. Imp. 2020;22:2345–2373.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Rogers RD, Reh CM, Breysse P. Advancing per-and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations. J. Exp. Sci. Envir. Epi. 2021;31:961–971. doi: 10.1038/s41370-021-00316-6.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41370-021-00316-6

Citation: Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per-and polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea food web. Envir. Poll. 2007;148:360–371. doi: 10.1016/j.envpol.2006.09.021.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2006.09.021

Citation: Fenton SE, et al. Per‐and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Envir. Tox. Chem. 2021;40:606–630. doi: 10.1002/etc.4890.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4890

Citation: Kucharzyk KH, Darlington R, Benotti M, Deeb R, Hawley E. Novel treatment technologies for PFAS compounds: A critical review. J. Environ. Manage. 2017;204:757–764. doi: 10.1016/j.jenvman.2017.08.016.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jenvman.2017.08.016

Citation: National Academies of Sciences, Engineering, and Medicine (NASEM), Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. 10.17226/26156 (2022).
Title: None
PMID: None
PMCID: None
DOI: 10.17226/26156

Citation: Rahman MF, Peldszus S, Anderson WB. Behaviour and fate of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in drinking water treatment: A review. Water Res. 2014;50:318–340. doi: 10.1016/j.watres.2013.10.045.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2013.10.045

Citation: De Silva AO, et al. PFAS exposure pathways for humans and wildlife: a synthesis of current knowledge and key gaps in understanding. Environ. Tox. Chem. 2021;40:631–657. doi: 10.1002/etc.4935.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4935

Citation: Olsen GW, et al. Per-and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000–2015. Environ. Res. 2017;157:87–95. doi: 10.1016/j.envres.2017.05.013.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2017.05.013

Citation: Domingo JL, Nadal M. Human exposure to per-and polyfluoroalkyl substances (PFAS) through drinking water: a review of the recent scientific literature. Environ. Res. 2019;177:108648–108648. doi: 10.1016/j.envres.2019.108648.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2019.108648

Citation: Hepburn E, et al. Contamination of groundwater with per-and polyfluoroalkyl substances (PFAS) from legacy landfills in an urban re-development precinct. Environ. Poll. 2019;248:101–113. doi: 10.1016/j.envpol.2019.02.018.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2019.02.018

Citation: Bai X, Son Y. Perfluoroalkyl substances (PFAS) in surface water and sediments from two urban watersheds in Nevada, USA. Sci. Tot. Envir. 2021;751:141622–141622. doi: 10.1016/j.scitotenv.2020.141622.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2020.141622

Citation: Li Y, et al. Formation and fate of perfluoroalkyl acids (PFAAs) in a laboratory-scale urban wastewater system. Water Res. 2022;216:118295–118295. doi: 10.1016/j.watres.2022.118295.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2022.118295

Citation: Hale SE, et al. Sorbent amendment as a remediation strategy to reduce PFAS mobility and leaching in a contaminated sandy soil from a Norwegian firefighting training facility. Chemosphere. 2017;171:9–18. doi: 10.1016/j.chemosphere.2016.12.057.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2016.12.057

Citation: Barber JL, et al. Analysis of per-and polyfluorinated alkyl substances in air samples from Northwest Europe. J. Environ. Monit. 2007;9:530–541. doi: 10.1039/b701417a.
Title: None
PMID: None
PMCID: None
DOI: 10.1039/b701417a

Citation: Koch A, et al. Point source characterization of per-and polyfluoroalkyl substances (PFASs) and extractable organofluorine (EOF) in freshwater and aquatic invertebrates. Environ. Sci.-Proc. Imp. 2019;21:1887–1898.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pétré MA, et al. Per-and polyfluoroalkyl substance (PFAS) transport from groundwater to streams near a PFAS manufacturing facility in North Carolina, USA. Environ. Sci. Tech. 2021;55:5848–5856. doi: 10.1021/acs.est.0c07978.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c07978

Citation: Ahrens L, Norström K, Viktor T, Cousins AP, Josefsson S. Stockholm Arlanda Airport as a source of per-and polyfluoroalkyl substances to water, sediment and fish. Chemosphere. 2015;129:33–38. doi: 10.1016/j.chemosphere.2014.03.136.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2014.03.136

Citation: Adamson DT, et al. Mass-based, field-scale demonstration of PFAS retention within AFFF-associated source areas. Environ. Sci. Tech. 2020;54:15768–15777. doi: 10.1021/acs.est.0c04472.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c04472

Citation: Quinnan J, et al. Application of PFAS‐mobile lab to support adaptive characterization and flux‐based conceptual site models at AFFF releases. Remed. J. 2021;31:7–26. doi: 10.1002/rem.21680.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/rem.21680

Citation: Schroeder T, Bond D, Foley J. PFAS soil and groundwater contamination via industrial airborne emission and land deposition in SW Vermont and Eastern New York State, USA. Environ. Sci.-Proc. Imp. 2021;23:291–301.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hale SE, Canivet B, Rundberget T, Langberg HA, Allan IJ. Using passive samplers to track Per and Polyfluoroalkyl Substances (PFAS) emissions from the paper industry: laboratory calibration and field verification. Front. Env. Sci. 2021;9:621–629. doi: 10.3389/fenvs.2021.796026.
Title: None
PMID: None
PMCID: None
DOI: 10.3389/fenvs.2021.796026

Citation: Hu XC, et al. Detection of poly-and perfluoroalkyl substances (PFASs) in US drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. Environ. Sci. Tech. Let. 2016;3:344–350. doi: 10.1021/acs.estlett.6b00260.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.estlett.6b00260

Citation: Ojha S, et al. A geospatial and binomial logistic regression model to prioritize sampling for per‐and polyfluorinated alkyl substances in public water systems. Integr. Environ. Assess. 2023;19:163–174. doi: 10.1002/ieam.4614.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/ieam.4614

Citation: Ebert JC, Altman RB. Robust recognition of zinc binding sites in proteins. Protein Sci. 2008;17:54–65. doi: 10.1110/ps.073138508.
Title: None
PMID: None
PMCID: None
DOI: 10.1110/ps.073138508

Citation: Wilkinson MD, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data. 2016;3:1–9. doi: 10.1038/sdata.2016.18.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/sdata.2016.18

Citation: Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur. J. Hum. Genet. 2018;26:931–936. doi: 10.1038/s41431-018-0160-0.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41431-018-0160-0

Citation: Thompson P. T., Ojha S., Powell C. D., Pennell K. G. & Moseley H. N. B. A proposed FAIR approach for disseminating geospatial information system maps. Accepted Sci. Data (2023).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zsóka Á, Szerényi ZM, Széchy A, Kocsis T. Greening due to environmental education? Environmental knowledge, attitudes, consumer behavior and everyday pro-environmental activities of Hungarian high school and university students. J. Clean. Prod. 2013;48:126–138. doi: 10.1016/j.jclepro.2012.11.030.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jclepro.2012.11.030

Citation: Guelfo JL, Adamson DT. Evaluation of a national data set for insights into sources, composition, and concentrations of per-and polyfluoroalkyl substances (PFASs) in US drinking water. Environ, Poll. 2018;236:505–513. doi: 10.1016/j.envpol.2018.01.066.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2018.01.066

Citation: Ohja S, Thompson PT, Powell CD, Moselet HNB, Pennell KP. 2022. A FAIR approach to detect and share PFAS hot-spot areas and water systems in Kentucky. Figshare.
Title: None
PMID: None
PMCID: None
DOI: 10.6084/m9.figshare.15218958


Authors: Hunter Moseley
Grants: None Found
Abstract: None
Conclusions: None
Copyrights: None
DOI: None
Journal: None
Keywords: None
Methods: None
PMID: None
Results: None
Title: Plk1 phosphorylation of PHGDH to regulate serine metabolism
PMCID: None
Publication Year: 2023
Publication Month: None
Publication Day: None
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Moseley, Hunter
Last Author: Moseley, Hunter
Pub_Authors: 
Moseley, Hunter None kentucky
References: None

Authors: Justin F Creeden, Zachary A Kipp, Mei Xu, Robert M Flight, Hunter N B Moseley, Genesee J Martinez, Wang-Hsin Lee, Khaled Alganem, Ali S Imami, Megan R McMullen, Sanjoy Roychowdhury, Atta M Nawabi, Jennifer A Hipp, Samir Softic, Steven A Weinman, Robert McCullumsmith, Laura E Nagy, Terry D Hinds
Grants: R01 MH121102, R01 AG057598, R01 DK121797, R01 MH107487, P30 CA177558, P50 AA024333
Abstract: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks.
We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Conclusions: None
Copyrights: © 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
DOI: 10.1002/hep.32467
Journal: Hepatology (Baltimore, Md.)
Keywords: []
Methods: None
PMID: 35313030
Results: None
Title: Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.
PMCID: PMC9489820
Publication Year: 2022
Publication Month: 3
Publication Day: 22
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Creeden, Justin F
Last Author: Hinds, Terry D
Pub_Authors: 
Creeden, Justin F JF Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Kipp, Zachary A ZA Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Xu, Mei M Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Flight, Robert M RM Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Moseley, Hunter N B HNB Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Center for Clinical and Translational Science, University of Kentucky, Lexington, Kentucky, USA.
Martinez, Genesee J GJ Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lee, Wang-Hsin WH Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Alganem, Khaled K Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Imami, Ali S AS Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
McMullen, Megan R MR Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Roychowdhury, Sanjoy S Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Nawabi, Atta M AM Division of Transplant and Hepatobiliary, Department of Surgery, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Hipp, Jennifer A JA Strata Oncology, Ann Arbor, Michigan, USA.
Softic, Samir S Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Department of Pediatrics, University of Kentucky, Lexington, Kentucky, USA.
Weinman, Steven A SA Department of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
McCullumsmith, Robert R Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Neurosciences Institute, ProMedica, Toledo, Ohio, USA.
Nagy, Laura E LE Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Gastroenterology and Hepatology, Center for Liver Disease Research, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Hinds, Terry D TD Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
References: 
Citation: Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Schuppan D, Ashfaq‐Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68–69:435–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Eslam M, Sanyal AJ, George J, International Consensus P . MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 e1991.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Hipp JA, Hong S, Mitchell ZL, Franco NR, et al. Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet‐induced obesity. Am J Physiol Regul Integr Comp Physiol. 2019;317:R733–R745.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. Bilirubin nanoparticles reduce diet‐induced hepatic steatosis, improve fat utilization, and increase plasma beta‐hydroxybutyrate. Front Pharmacol. 2020;11:594574.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Hinds TD Jr. Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:9493.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hamoud AR, Weaver L, Stec DE, Hinds TD Jr. Bilirubin in the liver‐gut signaling axis. Trends Endocrinol Metab. 2018;29:140–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Hosick PA, Hankins MW, Nestor‐Kalinoski A, Stec DE. Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha. Am J Physiol Endocrinol Metab. 2017;312:E244–E252.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD, Sodhi K, Meadows C, Fedorova L, Puri N, Kim DH, et al. Increased HO‐1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring). 2014;22:705–12.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Weaver L, Hamoud AR, Stec DE, Hinds TD Jr. Biliverdin reductase and bilirubin in hepatic disease. Am J Physiol Gastrointest Liver Physiol. 2018;314:G668–G676.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med. 2005;117:237–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pritchard MT, Nagy LE. Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr‐1‐deficient mice. Am J Pathol. 2010;176:2743–52.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Frangogiannis N. Transforming growth factor‐beta in tissue fibrosis. J Exp Med. 2020;217:e20190103.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6‐EGFR‐induced Kupffer cells secrete TGF‐beta1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C‐MYC/EZH2 pathway in liver fibrosis. J Cell Mol Med. 2018;22:5050–61.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Li H‐G, You P‐T, Xia YU, Cai YU, Tu Y‐J, Wang M‐H, et al. Yu Gan long ameliorates hepatic fibrosis by inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 signaling pathways in CCl4‐induced liver fibrosis rats. Curr Med Sci. 2020;40:539–47.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Carpino G, Morini S, Ginannicorradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha‐SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349–56.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014;34:185–92.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Moll S, Desmoulière A, Moeller MJ, Pache J‐C, Badi L, Arcadu F, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta Mol Cell Res. 2019;1866:118474.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu S‐H, et al. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int J Mol Sci. 2020;21:8823.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Svegliati‐Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Peterson SW, Angelico M, Masella R, Foster K, Gandin C, Cantafora A. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients. Ital J Gastroenterol. 1992;24:65–71.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Okada Y. Increased insulin binding to erythrocytes in chronic liver disease. Acta Med Okayama. 1981;35:155–64.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Petrides AS, Passlack W, Reinauer H, Stremmel W, Strohmeyer G. Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis. Klin Wochenschr. 1987;65:873–8.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Teng CS, Ho PW, Yeung RT. Down‐regulation of insulin receptors in postnecrotic cirrhosis of liver. J Clin Endocrinol Metab. 1982;55:524–30.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Greco AV, Bertoli A, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG. Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes. Horm Metab Res. 1980;12:577–81.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Harewood MS, Proietto J, Dudley F, Alford FP. Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes. Metabolism. 1982;31:1241–6.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484–95.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yen FS, Lai JN, Wei JC, Chiu LT, Hsu CC, Hou MC, et al. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis? BMC Gastroenterol. 2021;21:263.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Meroni M, Baselli G, Bassani G, Rametta R, Pietrelli A, et al. Insulin resistance promotes Lysyl oxidase like 2 induction and fibrosis accumulation in non‐alcoholic fatty liver disease. Clin Sci (Lond). 2017;131:1301–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non‐alcoholic fatty liver disease. Gut. 2010;59:267–73.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr. Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem. 2014;289:17885–94.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Smedlund KB, Sanchez ER, Hinds TD Jr. FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol Metab. 2021;32:862–74.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Nestor‐Kalinoski AL, Donald MC, Mitchell ZL, Creeden JF, et al. Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice. Biomolecules. 2020;10:387.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Burns KA, Hosick PA, McBeth L, Nestor‐Kalinoski A, Drummond HA, et al. Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator‐activated receptor (PPAR) alpha. J Biol Chem. 2016;291:25179–91.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: O'Brien L, Hosick PA, John K, Stec DE, Hinds TD Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab. 2015;26:212–20.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai CX, Buddha H, Castelino‐Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of insulin‐PI3K/Akt‐p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci. 2017;62:968–78.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zhang F, Zhang Z, Kong D, Zhang X, Chen LI, Zhu X, et al. Tetramethylpyrazine reduces glucose and insulin‐induced activation of hepatic stellate cells by inhibiting insulin receptor‐mediated PI3K/AKT and ERK pathways. Mol Cell Endocrinol. 2014;382:197–204.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Mateus T, Martins F, Nunes A, Herdeiro MT, Rebelo S. Metabolic alterations in myotonic dystrophy type 1 and their correlation with lipin. Int J Environ Res Public Health. 2021;18:1794.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, et al. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One. 2007;2:e1134.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Bhardwaj RR, Duchini A. Non‐alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep Gastroenterol. 2010;4:100–3.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yang J, Zhang X, Yi L, Yang L, Wang WE, Zeng C, et al. Hepatic PKA inhibition accelerates the lipid accumulation in liver. Nutr Metab (Lond). 2019;16:69.
Title: None
PMID: None
PMCID: None
DOI: None


Authors: Sweta Ojha, P Travis Thompson, Christian D Powell, Hunter N B Moseley, Kelly G Pennell
Grants: P42 ES007380, 2020026
Abstract: Exposure to per- and polyfluoroalkyl substances (PFAS) in drinking water is widely recognized as a public health concern. Decision-makers who are responsible for managing PFAS drinking water risks lack the tools to acquire the information they need. In response to this need, we provide a detailed description of a Kentucky dataset that allows decision-makers to visualize potential hot-spot areas and evaluate drinking water systems that may be susceptible to PFAS contamination. The dataset includes information extracted from publicly available sources to create five different maps in ArcGIS Online and highlights potential sources of PFAS contamination in the environment in relation to drinking water systems. As datasets of PFAS drinking water sampling continue to grow as part of evolving regulatory requirements, we used this Kentucky dataset as an example to promote the reuse of this dataset and others like it. We incorporated the FAIR (Findable, Accessible, Interoperable, and Reusable) principles by creating a Figshare item that includes all data and associated metadata with these five ArcGIS maps.
Conclusions: None
Copyrights: © 2023. The Author(s).
DOI: 10.1038/s41597-023-02277-x
Journal: Scientific data
Keywords: []
Methods: None
PMID: 37328532
Results: None
Title: Identifying and sharing per-and polyfluoroalkyl substances hot-spot areas and exposures in drinking water.
PMCID: PMC10275912
Publication Year: 2023
Publication Month: 6
Publication Day: 17
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Ojha, Sweta
Last Author: Pennell, Kelly G
Pub_Authors: 
Ojha, Sweta S University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Thompson, P Travis PT University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Powell, Christian D CD University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Computer Science (Data Science Program), Lexington, Kentucky, USA.
Moseley, Hunter N B HNB University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington, Kentucky, USA.
Pennell, Kelly G KG University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA. kellypennell@uky.edu.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA. kellypennell@uky.edu.
References: 
Citation: Environmental Protection Agency (EPA), PFAS Strategic Roadmap: EPA’s Commitments to Action 2021–2024. https://www.epa.gov/system/files/documents/2021-10/pfas-roadmap_final-508.pdf (2021).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Da Silva BF, Ahmadireskety A, Aristizabal-Henao JJ, Bowden JA. A rapid and simple method to quantify per-and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates. MethodsX. 2020;7:101111–10111. doi: 10.1016/j.mex.2020.101111.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.mex.2020.101111

Citation: Hagstrom AL, et al. Yale School of Public Health Symposium: an overview of the challenges and opportunities associated with per-and polyfluoroalkyl substances (PFAS) Sci. Total Envir. 2021;778:146192. doi: 10.1016/j.scitotenv.2021.146192.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2021.146192

Citation: Groffen T, et al. A rapid method for the detection and quantification of legacy and emerging per-and polyfluoroalkyl substances (PFAS) in bird feathers using UPLC-MS/MS. J. Chromatogr. B. 2021;1172:122653. doi: 10.1016/j.jchromb.2021.122653.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jchromb.2021.122653

Citation: Glüge J, et al. An overview of the uses of per-and polyfluoroalkyl substances (PFAS) Envir. Sci.-Proc. Imp. 2020;22:2345–2373.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Rogers RD, Reh CM, Breysse P. Advancing per-and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations. J. Exp. Sci. Envir. Epi. 2021;31:961–971. doi: 10.1038/s41370-021-00316-6.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41370-021-00316-6

Citation: Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per-and polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea food web. Envir. Poll. 2007;148:360–371. doi: 10.1016/j.envpol.2006.09.021.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2006.09.021

Citation: Fenton SE, et al. Per‐and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Envir. Tox. Chem. 2021;40:606–630. doi: 10.1002/etc.4890.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4890

Citation: Kucharzyk KH, Darlington R, Benotti M, Deeb R, Hawley E. Novel treatment technologies for PFAS compounds: A critical review. J. Environ. Manage. 2017;204:757–764. doi: 10.1016/j.jenvman.2017.08.016.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jenvman.2017.08.016

Citation: National Academies of Sciences, Engineering, and Medicine (NASEM), Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. 10.17226/26156 (2022).
Title: None
PMID: None
PMCID: None
DOI: 10.17226/26156

Citation: Rahman MF, Peldszus S, Anderson WB. Behaviour and fate of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in drinking water treatment: A review. Water Res. 2014;50:318–340. doi: 10.1016/j.watres.2013.10.045.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2013.10.045

Citation: De Silva AO, et al. PFAS exposure pathways for humans and wildlife: a synthesis of current knowledge and key gaps in understanding. Environ. Tox. Chem. 2021;40:631–657. doi: 10.1002/etc.4935.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4935

Citation: Olsen GW, et al. Per-and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000–2015. Environ. Res. 2017;157:87–95. doi: 10.1016/j.envres.2017.05.013.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2017.05.013

Citation: Domingo JL, Nadal M. Human exposure to per-and polyfluoroalkyl substances (PFAS) through drinking water: a review of the recent scientific literature. Environ. Res. 2019;177:108648–108648. doi: 10.1016/j.envres.2019.108648.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2019.108648

Citation: Hepburn E, et al. Contamination of groundwater with per-and polyfluoroalkyl substances (PFAS) from legacy landfills in an urban re-development precinct. Environ. Poll. 2019;248:101–113. doi: 10.1016/j.envpol.2019.02.018.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2019.02.018

Citation: Bai X, Son Y. Perfluoroalkyl substances (PFAS) in surface water and sediments from two urban watersheds in Nevada, USA. Sci. Tot. Envir. 2021;751:141622–141622. doi: 10.1016/j.scitotenv.2020.141622.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2020.141622

Citation: Li Y, et al. Formation and fate of perfluoroalkyl acids (PFAAs) in a laboratory-scale urban wastewater system. Water Res. 2022;216:118295–118295. doi: 10.1016/j.watres.2022.118295.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2022.118295

Citation: Hale SE, et al. Sorbent amendment as a remediation strategy to reduce PFAS mobility and leaching in a contaminated sandy soil from a Norwegian firefighting training facility. Chemosphere. 2017;171:9–18. doi: 10.1016/j.chemosphere.2016.12.057.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2016.12.057

Citation: Barber JL, et al. Analysis of per-and polyfluorinated alkyl substances in air samples from Northwest Europe. J. Environ. Monit. 2007;9:530–541. doi: 10.1039/b701417a.
Title: None
PMID: None
PMCID: None
DOI: 10.1039/b701417a

Citation: Koch A, et al. Point source characterization of per-and polyfluoroalkyl substances (PFASs) and extractable organofluorine (EOF) in freshwater and aquatic invertebrates. Environ. Sci.-Proc. Imp. 2019;21:1887–1898.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pétré MA, et al. Per-and polyfluoroalkyl substance (PFAS) transport from groundwater to streams near a PFAS manufacturing facility in North Carolina, USA. Environ. Sci. Tech. 2021;55:5848–5856. doi: 10.1021/acs.est.0c07978.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c07978

Citation: Ahrens L, Norström K, Viktor T, Cousins AP, Josefsson S. Stockholm Arlanda Airport as a source of per-and polyfluoroalkyl substances to water, sediment and fish. Chemosphere. 2015;129:33–38. doi: 10.1016/j.chemosphere.2014.03.136.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2014.03.136

Citation: Adamson DT, et al. Mass-based, field-scale demonstration of PFAS retention within AFFF-associated source areas. Environ. Sci. Tech. 2020;54:15768–15777. doi: 10.1021/acs.est.0c04472.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c04472

Citation: Quinnan J, et al. Application of PFAS‐mobile lab to support adaptive characterization and flux‐based conceptual site models at AFFF releases. Remed. J. 2021;31:7–26. doi: 10.1002/rem.21680.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/rem.21680

Citation: Schroeder T, Bond D, Foley J. PFAS soil and groundwater contamination via industrial airborne emission and land deposition in SW Vermont and Eastern New York State, USA. Environ. Sci.-Proc. Imp. 2021;23:291–301.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hale SE, Canivet B, Rundberget T, Langberg HA, Allan IJ. Using passive samplers to track Per and Polyfluoroalkyl Substances (PFAS) emissions from the paper industry: laboratory calibration and field verification. Front. Env. Sci. 2021;9:621–629. doi: 10.3389/fenvs.2021.796026.
Title: None
PMID: None
PMCID: None
DOI: 10.3389/fenvs.2021.796026

Citation: Hu XC, et al. Detection of poly-and perfluoroalkyl substances (PFASs) in US drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. Environ. Sci. Tech. Let. 2016;3:344–350. doi: 10.1021/acs.estlett.6b00260.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.estlett.6b00260

Citation: Ojha S, et al. A geospatial and binomial logistic regression model to prioritize sampling for per‐and polyfluorinated alkyl substances in public water systems. Integr. Environ. Assess. 2023;19:163–174. doi: 10.1002/ieam.4614.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/ieam.4614

Citation: Ebert JC, Altman RB. Robust recognition of zinc binding sites in proteins. Protein Sci. 2008;17:54–65. doi: 10.1110/ps.073138508.
Title: None
PMID: None
PMCID: None
DOI: 10.1110/ps.073138508

Citation: Wilkinson MD, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data. 2016;3:1–9. doi: 10.1038/sdata.2016.18.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/sdata.2016.18

Citation: Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur. J. Hum. Genet. 2018;26:931–936. doi: 10.1038/s41431-018-0160-0.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41431-018-0160-0

Citation: Thompson P. T., Ojha S., Powell C. D., Pennell K. G. & Moseley H. N. B. A proposed FAIR approach for disseminating geospatial information system maps. Accepted Sci. Data (2023).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zsóka Á, Szerényi ZM, Széchy A, Kocsis T. Greening due to environmental education? Environmental knowledge, attitudes, consumer behavior and everyday pro-environmental activities of Hungarian high school and university students. J. Clean. Prod. 2013;48:126–138. doi: 10.1016/j.jclepro.2012.11.030.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jclepro.2012.11.030

Citation: Guelfo JL, Adamson DT. Evaluation of a national data set for insights into sources, composition, and concentrations of per-and polyfluoroalkyl substances (PFASs) in US drinking water. Environ, Poll. 2018;236:505–513. doi: 10.1016/j.envpol.2018.01.066.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2018.01.066

Citation: Ohja S, Thompson PT, Powell CD, Moselet HNB, Pennell KP. 2022. A FAIR approach to detect and share PFAS hot-spot areas and water systems in Kentucky. Figshare.
Title: None
PMID: None
PMCID: None
DOI: 10.6084/m9.figshare.15218958


Authors: Hunter Moseley
Grants: None Found
Abstract: None
Conclusions: None
Copyrights: None
DOI: None
Journal: None
Keywords: None
Methods: None
PMID: None
Results: None
Title: Plk1 phosphorylation of PHGDH to regulate serine metabolism
PMCID: None
Publication Year: 2023
Publication Month: None
Publication Day: None
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Moseley, Hunter
Last Author: Moseley, Hunter
Pub_Authors: 
Moseley, Hunter None kentucky
References: None

Authors: Justin F Creeden, Zachary A Kipp, Mei Xu, Robert M Flight, Hunter N B Moseley, Genesee J Martinez, Wang-Hsin Lee, Khaled Alganem, Ali S Imami, Megan R McMullen, Sanjoy Roychowdhury, Atta M Nawabi, Jennifer A Hipp, Samir Softic, Steven A Weinman, Robert McCullumsmith, Laura E Nagy, Terry D Hinds
Grants: R01 MH121102, R01 AG057598, R01 DK121797, R01 MH107487, P30 CA177558, P50 AA024333
Abstract: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks.
We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Conclusions: None
Copyrights: © 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
DOI: 10.1002/hep.32467
Journal: Hepatology (Baltimore, Md.)
Keywords: []
Methods: None
PMID: 35313030
Results: None
Title: Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.
PMCID: PMC9489820
Publication Year: 2022
Publication Month: 3
Publication Day: 22
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Creeden, Justin F
Last Author: Hinds, Terry D
Pub_Authors: 
Creeden, Justin F JF Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Kipp, Zachary A ZA Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Xu, Mei M Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Flight, Robert M RM Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Moseley, Hunter N B HNB Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Center for Clinical and Translational Science, University of Kentucky, Lexington, Kentucky, USA.
Martinez, Genesee J GJ Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lee, Wang-Hsin WH Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Alganem, Khaled K Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Imami, Ali S AS Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
McMullen, Megan R MR Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Roychowdhury, Sanjoy S Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Nawabi, Atta M AM Division of Transplant and Hepatobiliary, Department of Surgery, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Hipp, Jennifer A JA Strata Oncology, Ann Arbor, Michigan, USA.
Softic, Samir S Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Department of Pediatrics, University of Kentucky, Lexington, Kentucky, USA.
Weinman, Steven A SA Department of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
McCullumsmith, Robert R Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Neurosciences Institute, ProMedica, Toledo, Ohio, USA.
Nagy, Laura E LE Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Gastroenterology and Hepatology, Center for Liver Disease Research, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Hinds, Terry D TD Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
References: 
Citation: Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Schuppan D, Ashfaq‐Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68–69:435–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Eslam M, Sanyal AJ, George J, International Consensus P . MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 e1991.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Hipp JA, Hong S, Mitchell ZL, Franco NR, et al. Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet‐induced obesity. Am J Physiol Regul Integr Comp Physiol. 2019;317:R733–R745.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. Bilirubin nanoparticles reduce diet‐induced hepatic steatosis, improve fat utilization, and increase plasma beta‐hydroxybutyrate. Front Pharmacol. 2020;11:594574.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Hinds TD Jr. Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:9493.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hamoud AR, Weaver L, Stec DE, Hinds TD Jr. Bilirubin in the liver‐gut signaling axis. Trends Endocrinol Metab. 2018;29:140–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Hosick PA, Hankins MW, Nestor‐Kalinoski A, Stec DE. Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha. Am J Physiol Endocrinol Metab. 2017;312:E244–E252.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD, Sodhi K, Meadows C, Fedorova L, Puri N, Kim DH, et al. Increased HO‐1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring). 2014;22:705–12.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Weaver L, Hamoud AR, Stec DE, Hinds TD Jr. Biliverdin reductase and bilirubin in hepatic disease. Am J Physiol Gastrointest Liver Physiol. 2018;314:G668–G676.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med. 2005;117:237–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pritchard MT, Nagy LE. Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr‐1‐deficient mice. Am J Pathol. 2010;176:2743–52.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Frangogiannis N. Transforming growth factor‐beta in tissue fibrosis. J Exp Med. 2020;217:e20190103.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6‐EGFR‐induced Kupffer cells secrete TGF‐beta1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C‐MYC/EZH2 pathway in liver fibrosis. J Cell Mol Med. 2018;22:5050–61.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Li H‐G, You P‐T, Xia YU, Cai YU, Tu Y‐J, Wang M‐H, et al. Yu Gan long ameliorates hepatic fibrosis by inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 signaling pathways in CCl4‐induced liver fibrosis rats. Curr Med Sci. 2020;40:539–47.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Carpino G, Morini S, Ginannicorradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha‐SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349–56.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014;34:185–92.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Moll S, Desmoulière A, Moeller MJ, Pache J‐C, Badi L, Arcadu F, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta Mol Cell Res. 2019;1866:118474.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu S‐H, et al. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int J Mol Sci. 2020;21:8823.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Svegliati‐Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Peterson SW, Angelico M, Masella R, Foster K, Gandin C, Cantafora A. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients. Ital J Gastroenterol. 1992;24:65–71.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Okada Y. Increased insulin binding to erythrocytes in chronic liver disease. Acta Med Okayama. 1981;35:155–64.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Petrides AS, Passlack W, Reinauer H, Stremmel W, Strohmeyer G. Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis. Klin Wochenschr. 1987;65:873–8.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Teng CS, Ho PW, Yeung RT. Down‐regulation of insulin receptors in postnecrotic cirrhosis of liver. J Clin Endocrinol Metab. 1982;55:524–30.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Greco AV, Bertoli A, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG. Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes. Horm Metab Res. 1980;12:577–81.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Harewood MS, Proietto J, Dudley F, Alford FP. Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes. Metabolism. 1982;31:1241–6.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484–95.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yen FS, Lai JN, Wei JC, Chiu LT, Hsu CC, Hou MC, et al. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis? BMC Gastroenterol. 2021;21:263.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Meroni M, Baselli G, Bassani G, Rametta R, Pietrelli A, et al. Insulin resistance promotes Lysyl oxidase like 2 induction and fibrosis accumulation in non‐alcoholic fatty liver disease. Clin Sci (Lond). 2017;131:1301–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non‐alcoholic fatty liver disease. Gut. 2010;59:267–73.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr. Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem. 2014;289:17885–94.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Smedlund KB, Sanchez ER, Hinds TD Jr. FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol Metab. 2021;32:862–74.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Nestor‐Kalinoski AL, Donald MC, Mitchell ZL, Creeden JF, et al. Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice. Biomolecules. 2020;10:387.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Burns KA, Hosick PA, McBeth L, Nestor‐Kalinoski A, Drummond HA, et al. Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator‐activated receptor (PPAR) alpha. J Biol Chem. 2016;291:25179–91.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: O'Brien L, Hosick PA, John K, Stec DE, Hinds TD Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab. 2015;26:212–20.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai CX, Buddha H, Castelino‐Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of insulin‐PI3K/Akt‐p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci. 2017;62:968–78.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zhang F, Zhang Z, Kong D, Zhang X, Chen LI, Zhu X, et al. Tetramethylpyrazine reduces glucose and insulin‐induced activation of hepatic stellate cells by inhibiting insulin receptor‐mediated PI3K/AKT and ERK pathways. Mol Cell Endocrinol. 2014;382:197–204.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Mateus T, Martins F, Nunes A, Herdeiro MT, Rebelo S. Metabolic alterations in myotonic dystrophy type 1 and their correlation with lipin. Int J Environ Res Public Health. 2021;18:1794.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, et al. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One. 2007;2:e1134.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Bhardwaj RR, Duchini A. Non‐alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep Gastroenterol. 2010;4:100–3.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yang J, Zhang X, Yi L, Yang L, Wang WE, Zeng C, et al. Hepatic PKA inhibition accelerates the lipid accumulation in liver. Nutr Metab (Lond). 2019;16:69.
Title: None
PMID: None
PMCID: None
DOI: None


Authors: Sweta Ojha, P Travis Thompson, Christian D Powell, Hunter N B Moseley, Kelly G Pennell
Grants: P42 ES007380, 2020026
Abstract: Exposure to per- and polyfluoroalkyl substances (PFAS) in drinking water is widely recognized as a public health concern. Decision-makers who are responsible for managing PFAS drinking water risks lack the tools to acquire the information they need. In response to this need, we provide a detailed description of a Kentucky dataset that allows decision-makers to visualize potential hot-spot areas and evaluate drinking water systems that may be susceptible to PFAS contamination. The dataset includes information extracted from publicly available sources to create five different maps in ArcGIS Online and highlights potential sources of PFAS contamination in the environment in relation to drinking water systems. As datasets of PFAS drinking water sampling continue to grow as part of evolving regulatory requirements, we used this Kentucky dataset as an example to promote the reuse of this dataset and others like it. We incorporated the FAIR (Findable, Accessible, Interoperable, and Reusable) principles by creating a Figshare item that includes all data and associated metadata with these five ArcGIS maps.
Conclusions: None
Copyrights: © 2023. The Author(s).
DOI: 10.1038/s41597-023-02277-x
Journal: Scientific data
Keywords: []
Methods: None
PMID: 37328532
Results: None
Title: Identifying and sharing per-and polyfluoroalkyl substances hot-spot areas and exposures in drinking water.
PMCID: PMC10275912
Publication Year: 2023
Publication Month: 6
Publication Day: 17
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Ojha, Sweta
Last Author: Pennell, Kelly G
Pub_Authors: 
Ojha, Sweta S University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Thompson, P Travis PT University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Powell, Christian D CD University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Computer Science (Data Science Program), Lexington, Kentucky, USA.
Moseley, Hunter N B HNB University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington, Kentucky, USA.
Pennell, Kelly G KG University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA. kellypennell@uky.edu.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA. kellypennell@uky.edu.
References: 
Citation: Environmental Protection Agency (EPA), PFAS Strategic Roadmap: EPA’s Commitments to Action 2021–2024. https://www.epa.gov/system/files/documents/2021-10/pfas-roadmap_final-508.pdf (2021).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Da Silva BF, Ahmadireskety A, Aristizabal-Henao JJ, Bowden JA. A rapid and simple method to quantify per-and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates. MethodsX. 2020;7:101111–10111. doi: 10.1016/j.mex.2020.101111.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.mex.2020.101111

Citation: Hagstrom AL, et al. Yale School of Public Health Symposium: an overview of the challenges and opportunities associated with per-and polyfluoroalkyl substances (PFAS) Sci. Total Envir. 2021;778:146192. doi: 10.1016/j.scitotenv.2021.146192.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2021.146192

Citation: Groffen T, et al. A rapid method for the detection and quantification of legacy and emerging per-and polyfluoroalkyl substances (PFAS) in bird feathers using UPLC-MS/MS. J. Chromatogr. B. 2021;1172:122653. doi: 10.1016/j.jchromb.2021.122653.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jchromb.2021.122653

Citation: Glüge J, et al. An overview of the uses of per-and polyfluoroalkyl substances (PFAS) Envir. Sci.-Proc. Imp. 2020;22:2345–2373.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Rogers RD, Reh CM, Breysse P. Advancing per-and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations. J. Exp. Sci. Envir. Epi. 2021;31:961–971. doi: 10.1038/s41370-021-00316-6.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41370-021-00316-6

Citation: Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per-and polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea food web. Envir. Poll. 2007;148:360–371. doi: 10.1016/j.envpol.2006.09.021.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2006.09.021

Citation: Fenton SE, et al. Per‐and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Envir. Tox. Chem. 2021;40:606–630. doi: 10.1002/etc.4890.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4890

Citation: Kucharzyk KH, Darlington R, Benotti M, Deeb R, Hawley E. Novel treatment technologies for PFAS compounds: A critical review. J. Environ. Manage. 2017;204:757–764. doi: 10.1016/j.jenvman.2017.08.016.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jenvman.2017.08.016

Citation: National Academies of Sciences, Engineering, and Medicine (NASEM), Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. 10.17226/26156 (2022).
Title: None
PMID: None
PMCID: None
DOI: 10.17226/26156

Citation: Rahman MF, Peldszus S, Anderson WB. Behaviour and fate of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in drinking water treatment: A review. Water Res. 2014;50:318–340. doi: 10.1016/j.watres.2013.10.045.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2013.10.045

Citation: De Silva AO, et al. PFAS exposure pathways for humans and wildlife: a synthesis of current knowledge and key gaps in understanding. Environ. Tox. Chem. 2021;40:631–657. doi: 10.1002/etc.4935.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4935

Citation: Olsen GW, et al. Per-and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000–2015. Environ. Res. 2017;157:87–95. doi: 10.1016/j.envres.2017.05.013.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2017.05.013

Citation: Domingo JL, Nadal M. Human exposure to per-and polyfluoroalkyl substances (PFAS) through drinking water: a review of the recent scientific literature. Environ. Res. 2019;177:108648–108648. doi: 10.1016/j.envres.2019.108648.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2019.108648

Citation: Hepburn E, et al. Contamination of groundwater with per-and polyfluoroalkyl substances (PFAS) from legacy landfills in an urban re-development precinct. Environ. Poll. 2019;248:101–113. doi: 10.1016/j.envpol.2019.02.018.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2019.02.018

Citation: Bai X, Son Y. Perfluoroalkyl substances (PFAS) in surface water and sediments from two urban watersheds in Nevada, USA. Sci. Tot. Envir. 2021;751:141622–141622. doi: 10.1016/j.scitotenv.2020.141622.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2020.141622

Citation: Li Y, et al. Formation and fate of perfluoroalkyl acids (PFAAs) in a laboratory-scale urban wastewater system. Water Res. 2022;216:118295–118295. doi: 10.1016/j.watres.2022.118295.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2022.118295

Citation: Hale SE, et al. Sorbent amendment as a remediation strategy to reduce PFAS mobility and leaching in a contaminated sandy soil from a Norwegian firefighting training facility. Chemosphere. 2017;171:9–18. doi: 10.1016/j.chemosphere.2016.12.057.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2016.12.057

Citation: Barber JL, et al. Analysis of per-and polyfluorinated alkyl substances in air samples from Northwest Europe. J. Environ. Monit. 2007;9:530–541. doi: 10.1039/b701417a.
Title: None
PMID: None
PMCID: None
DOI: 10.1039/b701417a

Citation: Koch A, et al. Point source characterization of per-and polyfluoroalkyl substances (PFASs) and extractable organofluorine (EOF) in freshwater and aquatic invertebrates. Environ. Sci.-Proc. Imp. 2019;21:1887–1898.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pétré MA, et al. Per-and polyfluoroalkyl substance (PFAS) transport from groundwater to streams near a PFAS manufacturing facility in North Carolina, USA. Environ. Sci. Tech. 2021;55:5848–5856. doi: 10.1021/acs.est.0c07978.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c07978

Citation: Ahrens L, Norström K, Viktor T, Cousins AP, Josefsson S. Stockholm Arlanda Airport as a source of per-and polyfluoroalkyl substances to water, sediment and fish. Chemosphere. 2015;129:33–38. doi: 10.1016/j.chemosphere.2014.03.136.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2014.03.136

Citation: Adamson DT, et al. Mass-based, field-scale demonstration of PFAS retention within AFFF-associated source areas. Environ. Sci. Tech. 2020;54:15768–15777. doi: 10.1021/acs.est.0c04472.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c04472

Citation: Quinnan J, et al. Application of PFAS‐mobile lab to support adaptive characterization and flux‐based conceptual site models at AFFF releases. Remed. J. 2021;31:7–26. doi: 10.1002/rem.21680.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/rem.21680

Citation: Schroeder T, Bond D, Foley J. PFAS soil and groundwater contamination via industrial airborne emission and land deposition in SW Vermont and Eastern New York State, USA. Environ. Sci.-Proc. Imp. 2021;23:291–301.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hale SE, Canivet B, Rundberget T, Langberg HA, Allan IJ. Using passive samplers to track Per and Polyfluoroalkyl Substances (PFAS) emissions from the paper industry: laboratory calibration and field verification. Front. Env. Sci. 2021;9:621–629. doi: 10.3389/fenvs.2021.796026.
Title: None
PMID: None
PMCID: None
DOI: 10.3389/fenvs.2021.796026

Citation: Hu XC, et al. Detection of poly-and perfluoroalkyl substances (PFASs) in US drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. Environ. Sci. Tech. Let. 2016;3:344–350. doi: 10.1021/acs.estlett.6b00260.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.estlett.6b00260

Citation: Ojha S, et al. A geospatial and binomial logistic regression model to prioritize sampling for per‐and polyfluorinated alkyl substances in public water systems. Integr. Environ. Assess. 2023;19:163–174. doi: 10.1002/ieam.4614.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/ieam.4614

Citation: Ebert JC, Altman RB. Robust recognition of zinc binding sites in proteins. Protein Sci. 2008;17:54–65. doi: 10.1110/ps.073138508.
Title: None
PMID: None
PMCID: None
DOI: 10.1110/ps.073138508

Citation: Wilkinson MD, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data. 2016;3:1–9. doi: 10.1038/sdata.2016.18.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/sdata.2016.18

Citation: Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur. J. Hum. Genet. 2018;26:931–936. doi: 10.1038/s41431-018-0160-0.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41431-018-0160-0

Citation: Thompson P. T., Ojha S., Powell C. D., Pennell K. G. & Moseley H. N. B. A proposed FAIR approach for disseminating geospatial information system maps. Accepted Sci. Data (2023).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zsóka Á, Szerényi ZM, Széchy A, Kocsis T. Greening due to environmental education? Environmental knowledge, attitudes, consumer behavior and everyday pro-environmental activities of Hungarian high school and university students. J. Clean. Prod. 2013;48:126–138. doi: 10.1016/j.jclepro.2012.11.030.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jclepro.2012.11.030

Citation: Guelfo JL, Adamson DT. Evaluation of a national data set for insights into sources, composition, and concentrations of per-and polyfluoroalkyl substances (PFASs) in US drinking water. Environ, Poll. 2018;236:505–513. doi: 10.1016/j.envpol.2018.01.066.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2018.01.066

Citation: Ohja S, Thompson PT, Powell CD, Moselet HNB, Pennell KP. 2022. A FAIR approach to detect and share PFAS hot-spot areas and water systems in Kentucky. Figshare.
Title: None
PMID: None
PMCID: None
DOI: 10.6084/m9.figshare.15218958


Authors: Hunter Moseley
Grants: None Found
Abstract: None
Conclusions: None
Copyrights: None
DOI: None
Journal: None
Keywords: None
Methods: None
PMID: None
Results: None
Title: Plk1 phosphorylation of PHGDH to regulate serine metabolism
PMCID: None
Publication Year: 2023
Publication Month: None
Publication Day: None
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Moseley, Hunter
Last Author: Moseley, Hunter
Pub_Authors: 
Moseley, Hunter None kentucky
References: None

Authors: Justin F Creeden, Zachary A Kipp, Mei Xu, Robert M Flight, Hunter N B Moseley, Genesee J Martinez, Wang-Hsin Lee, Khaled Alganem, Ali S Imami, Megan R McMullen, Sanjoy Roychowdhury, Atta M Nawabi, Jennifer A Hipp, Samir Softic, Steven A Weinman, Robert McCullumsmith, Laura E Nagy, Terry D Hinds
Grants: R01 MH121102, R01 AG057598, R01 DK121797, R01 MH107487, P30 CA177558, P50 AA024333
Abstract: Resolution of pathways that converge to induce deleterious effects in hepatic diseases, such as in the later stages, have potential antifibrotic effects that may improve outcomes. We aimed to explore whether humans and rodents display similar fibrotic signaling networks.
We assiduously mapped kinase pathways using 340 substrate targets, upstream bioinformatic analysis of kinase pathways, and over 2000 random sampling iterations using the PamGene PamStation kinome microarray chip technology. Using this technology, we characterized a large number of kinases with altered activity in liver fibrosis of both species. Gene expression and immunostaining analyses validated many of these kinases as bona fide signaling events. Surprisingly, the insulin receptor emerged as a considerable protein tyrosine kinase that is hyperactive in fibrotic liver disease in humans and rodents. Discoidin domain receptor tyrosine kinase, activated by collagen that increases during fibrosis, was another hyperactive protein tyrosine kinase in humans and rodents with fibrosis. The serine/threonine kinases found to be the most active in fibrosis were dystrophy type 1 protein kinase and members of the protein kinase family of kinases. We compared the fibrotic events over four models: humans with cirrhosis and three murine models with differing levels of fibrosis, including two models of fatty liver disease with emerging fibrosis. The data demonstrate a high concordance between human and rodent hepatic kinome signaling that focalizes, as shown by our network analysis of detrimental pathways.
Our findings establish a comprehensive kinase atlas for liver fibrosis, which identifies analogous signaling events conserved among humans and rodents.
Conclusions: None
Copyrights: © 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
DOI: 10.1002/hep.32467
Journal: Hepatology (Baltimore, Md.)
Keywords: []
Methods: None
PMID: 35313030
Results: None
Title: Hepatic kinome atlas: An in-depth identification of kinase pathways in liver fibrosis of humans and rodents.
PMCID: PMC9489820
Publication Year: 2022
Publication Month: 3
Publication Day: 22
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Creeden, Justin F
Last Author: Hinds, Terry D
Pub_Authors: 
Creeden, Justin F JF Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Kipp, Zachary A ZA Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Xu, Mei M Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Flight, Robert M RM Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Moseley, Hunter N B HNB Department of Molecular & Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Resource Center for Stable Isotope Resolved Metabolomics, University of Kentucky, Lexington, Kentucky, USA.
Institute for Biomedical Informatics, University of Kentucky, Lexington, Kentucky, USA.
Center for Clinical and Translational Science, University of Kentucky, Lexington, Kentucky, USA.
Martinez, Genesee J GJ Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Lee, Wang-Hsin WH Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Alganem, Khaled K Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Imami, Ali S AS Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
McMullen, Megan R MR Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Roychowdhury, Sanjoy S Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Nawabi, Atta M AM Division of Transplant and Hepatobiliary, Department of Surgery, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Hipp, Jennifer A JA Strata Oncology, Ann Arbor, Michigan, USA.
Softic, Samir S Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Department of Pediatrics, University of Kentucky, Lexington, Kentucky, USA.
Weinman, Steven A SA Department of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
McCullumsmith, Robert R Department of Neurosciences, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Neurosciences Institute, ProMedica, Toledo, Ohio, USA.
Nagy, Laura E LE Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Gastroenterology and Hepatology, Center for Liver Disease Research, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Molecular Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Hinds, Terry D TD Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Barnstable Brown Diabetes Center, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
References: 
Citation: Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9:875.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Schuppan D, Ashfaq‐Khan M, Yang AT, Kim YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol. 2018;68–69:435–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25:195–206.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Eslam M, Sanyal AJ, George J, International Consensus P . MAFLD: a consensus‐driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014 e1991.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Hipp JA, Hong S, Mitchell ZL, Franco NR, et al. Loss of hepatic PPARalpha promotes inflammation and serum hyperlipidemia in diet‐induced obesity. Am J Physiol Regul Integr Comp Physiol. 2019;317:R733–R745.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Creeden JF, Gordon DM, Stec DF, Donald MC, Stec DE. Bilirubin nanoparticles reduce diet‐induced hepatic steatosis, improve fat utilization, and increase plasma beta‐hydroxybutyrate. Front Pharmacol. 2020;11:594574.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Hinds TD Jr. Natural product heme oxygenase inducers as treatment for nonalcoholic fatty liver disease. Int J Mol Sci. 2020;21:9493.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hamoud AR, Weaver L, Stec DE, Hinds TD Jr. Bilirubin in the liver‐gut signaling axis. Trends Endocrinol Metab. 2018;29:140–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Hosick PA, Hankins MW, Nestor‐Kalinoski A, Stec DE. Mice with hyperbilirubinemia due to Gilbert's Syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARalpha. Am J Physiol Endocrinol Metab. 2017;312:E244–E252.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD, Sodhi K, Meadows C, Fedorova L, Puri N, Kim DH, et al. Increased HO‐1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. Obesity (Silver Spring). 2014;22:705–12.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Weaver L, Hamoud AR, Stec DE, Hinds TD Jr. Biliverdin reductase and bilirubin in hepatic disease. Am J Physiol Gastrointest Liver Physiol. 2018;314:G668–G676.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med. 2005;117:237–50.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pritchard MT, Nagy LE. Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr‐1‐deficient mice. Am J Pathol. 2010;176:2743–52.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Frangogiannis N. Transforming growth factor‐beta in tissue fibrosis. J Exp Med. 2020;217:e20190103.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, et al. CXCL6‐EGFR‐induced Kupffer cells secrete TGF‐beta1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C‐MYC/EZH2 pathway in liver fibrosis. J Cell Mol Med. 2018;22:5050–61.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Li H‐G, You P‐T, Xia YU, Cai YU, Tu Y‐J, Wang M‐H, et al. Yu Gan long ameliorates hepatic fibrosis by inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 signaling pathways in CCl4‐induced liver fibrosis rats. Curr Med Sci. 2020;40:539–47.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Carpino G, Morini S, Ginannicorradini S, Franchitto A, Merli M, Siciliano M, et al. Alpha‐SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005;37:349–56.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Borza CM, Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014;34:185–92.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Moll S, Desmoulière A, Moeller MJ, Pache J‐C, Badi L, Arcadu F, et al. DDR1 role in fibrosis and its pharmacological targeting. Biochim Biophys Acta Mol Cell Res. 2019;1866:118474.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Creeden JF, Alganem K, Imami AS, Henkel ND, Brunicardi FC, Liu S‐H, et al. Emerging kinase therapeutic targets in pancreatic ductal adenocarcinoma and pancreatic cancer desmoplasia. Int J Mol Sci. 2020;21:8823.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Svegliati‐Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–51.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Peterson SW, Angelico M, Masella R, Foster K, Gandin C, Cantafora A. Altered insulin receptor processing and membrane lipid composition in erythrocytes of cirrhotic patients. Ital J Gastroenterol. 1992;24:65–71.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Okada Y. Increased insulin binding to erythrocytes in chronic liver disease. Acta Med Okayama. 1981;35:155–64.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Petrides AS, Passlack W, Reinauer H, Stremmel W, Strohmeyer G. Insulin binding to erythrocytes in hyperinsulinemic patients with precirrhotic hemochromatosis and cirrhosis. Klin Wochenschr. 1987;65:873–8.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Teng CS, Ho PW, Yeung RT. Down‐regulation of insulin receptors in postnecrotic cirrhosis of liver. J Clin Endocrinol Metab. 1982;55:524–30.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Greco AV, Bertoli A, Ghirlanda G, Manna R, Altomonte L, Rebuzzi AG. Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes. Horm Metab Res. 1980;12:577–81.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Harewood MS, Proietto J, Dudley F, Alford FP. Insulin action and cirrhosis: insulin binding and lipogenesis in isolated adipocytes. Metabolism. 1982;31:1241–6.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484–95.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yen FS, Lai JN, Wei JC, Chiu LT, Hsu CC, Hou MC, et al. Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis? BMC Gastroenterol. 2021;21:263.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Meroni M, Baselli G, Bassani G, Rametta R, Pietrelli A, et al. Insulin resistance promotes Lysyl oxidase like 2 induction and fibrosis accumulation in non‐alcoholic fatty liver disease. Clin Sci (Lond). 2017;131:1301–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non‐alcoholic fatty liver disease. Gut. 2010;59:267–73.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr. Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem. 2014;289:17885–94.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Smedlund KB, Sanchez ER, Hinds TD Jr. FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol Metab. 2021;32:862–74.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Stec DE, Gordon DM, Nestor‐Kalinoski AL, Donald MC, Mitchell ZL, Creeden JF, et al. Biliverdin reductase A (BVRA) knockout in adipocytes induces hypertrophy and reduces mitochondria in white fat of obese mice. Biomolecules. 2020;10:387.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hinds TD Jr, Burns KA, Hosick PA, McBeth L, Nestor‐Kalinoski A, Drummond HA, et al. Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3beta phosphorylation of serine 73 of peroxisome proliferator‐activated receptor (PPAR) alpha. J Biol Chem. 2016;291:25179–91.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: O'Brien L, Hosick PA, John K, Stec DE, Hinds TD Jr. Biliverdin reductase isozymes in metabolism. Trends Endocrinol Metab. 2015;26:212–20.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Cai CX, Buddha H, Castelino‐Prabhu S, Zhang Z, Britton RS, Bacon BR, et al. Activation of insulin‐PI3K/Akt‐p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci. 2017;62:968–78.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zhang F, Zhang Z, Kong D, Zhang X, Chen LI, Zhu X, et al. Tetramethylpyrazine reduces glucose and insulin‐induced activation of hepatic stellate cells by inhibiting insulin receptor‐mediated PI3K/AKT and ERK pathways. Mol Cell Endocrinol. 2014;382:197–204.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Mateus T, Martins F, Nunes A, Herdeiro MT, Rebelo S. Metabolic alterations in myotonic dystrophy type 1 and their correlation with lipin. Int J Environ Res Public Health. 2021;18:1794.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Llagostera E, Catalucci D, Marti L, Liesa M, Camps M, Ciaraldi TP, et al. Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One. 2007;2:e1134.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Bhardwaj RR, Duchini A. Non‐alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep Gastroenterol. 2010;4:100–3.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal. 2018;49:105–15.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Yang J, Zhang X, Yi L, Yang L, Wang WE, Zeng C, et al. Hepatic PKA inhibition accelerates the lipid accumulation in liver. Nutr Metab (Lond). 2019;16:69.
Title: None
PMID: None
PMCID: None
DOI: None


Authors: Sweta Ojha, P Travis Thompson, Christian D Powell, Hunter N B Moseley, Kelly G Pennell
Grants: P42 ES007380, 2020026
Abstract: Exposure to per- and polyfluoroalkyl substances (PFAS) in drinking water is widely recognized as a public health concern. Decision-makers who are responsible for managing PFAS drinking water risks lack the tools to acquire the information they need. In response to this need, we provide a detailed description of a Kentucky dataset that allows decision-makers to visualize potential hot-spot areas and evaluate drinking water systems that may be susceptible to PFAS contamination. The dataset includes information extracted from publicly available sources to create five different maps in ArcGIS Online and highlights potential sources of PFAS contamination in the environment in relation to drinking water systems. As datasets of PFAS drinking water sampling continue to grow as part of evolving regulatory requirements, we used this Kentucky dataset as an example to promote the reuse of this dataset and others like it. We incorporated the FAIR (Findable, Accessible, Interoperable, and Reusable) principles by creating a Figshare item that includes all data and associated metadata with these five ArcGIS maps.
Conclusions: None
Copyrights: © 2023. The Author(s).
DOI: 10.1038/s41597-023-02277-x
Journal: Scientific data
Keywords: []
Methods: None
PMID: 37328532
Results: None
Title: Identifying and sharing per-and polyfluoroalkyl substances hot-spot areas and exposures in drinking water.
PMCID: PMC10275912
Publication Year: 2023
Publication Month: 6
Publication Day: 17
Author First: Hunter
Author Last: Moseley
Name Search: Hunter Moseley
Email: hunter.moseley@gmail.com
First Author: Ojha, Sweta
Last Author: Pennell, Kelly G
Pub_Authors: 
Ojha, Sweta S University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Thompson, P Travis PT University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
Powell, Christian D CD University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Computer Science (Data Science Program), Lexington, Kentucky, USA.
Moseley, Hunter N B HNB University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA.
University of Kentucky, Department of Molecular and Cellular Biochemistry, Lexington, Kentucky, USA.
Pennell, Kelly G KG University of Kentucky, College of Engineering, Department of Civil Engineering, Lexington, Kentucky, USA. kellypennell@uky.edu.
University of Kentucky Superfund Research Center (UKSRC), Lexington, Kentucky, USA. kellypennell@uky.edu.
References: 
Citation: Environmental Protection Agency (EPA), PFAS Strategic Roadmap: EPA’s Commitments to Action 2021–2024. https://www.epa.gov/system/files/documents/2021-10/pfas-roadmap_final-508.pdf (2021).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Da Silva BF, Ahmadireskety A, Aristizabal-Henao JJ, Bowden JA. A rapid and simple method to quantify per-and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates. MethodsX. 2020;7:101111–10111. doi: 10.1016/j.mex.2020.101111.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.mex.2020.101111

Citation: Hagstrom AL, et al. Yale School of Public Health Symposium: an overview of the challenges and opportunities associated with per-and polyfluoroalkyl substances (PFAS) Sci. Total Envir. 2021;778:146192. doi: 10.1016/j.scitotenv.2021.146192.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2021.146192

Citation: Groffen T, et al. A rapid method for the detection and quantification of legacy and emerging per-and polyfluoroalkyl substances (PFAS) in bird feathers using UPLC-MS/MS. J. Chromatogr. B. 2021;1172:122653. doi: 10.1016/j.jchromb.2021.122653.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jchromb.2021.122653

Citation: Glüge J, et al. An overview of the uses of per-and polyfluoroalkyl substances (PFAS) Envir. Sci.-Proc. Imp. 2020;22:2345–2373.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Rogers RD, Reh CM, Breysse P. Advancing per-and polyfluoroalkyl substances (PFAS) research: an overview of ATSDR and NCEH activities and recommendations. J. Exp. Sci. Envir. Epi. 2021;31:961–971. doi: 10.1038/s41370-021-00316-6.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41370-021-00316-6

Citation: Haukås M, Berger U, Hop H, Gulliksen B, Gabrielsen GW. Bioaccumulation of per-and polyfluorinated alkyl substances (PFAS) in selected species from the Barents Sea food web. Envir. Poll. 2007;148:360–371. doi: 10.1016/j.envpol.2006.09.021.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2006.09.021

Citation: Fenton SE, et al. Per‐and polyfluoroalkyl substance toxicity and human health review: Current state of knowledge and strategies for informing future research. Envir. Tox. Chem. 2021;40:606–630. doi: 10.1002/etc.4890.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4890

Citation: Kucharzyk KH, Darlington R, Benotti M, Deeb R, Hawley E. Novel treatment technologies for PFAS compounds: A critical review. J. Environ. Manage. 2017;204:757–764. doi: 10.1016/j.jenvman.2017.08.016.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jenvman.2017.08.016

Citation: National Academies of Sciences, Engineering, and Medicine (NASEM), Guidance on PFAS Exposure, Testing, and Clinical Follow-Up. Washington, DC: The National Academies Press. 10.17226/26156 (2022).
Title: None
PMID: None
PMCID: None
DOI: 10.17226/26156

Citation: Rahman MF, Peldszus S, Anderson WB. Behaviour and fate of perfluoroalkyl and polyfluoroalkyl substances (PFASs) in drinking water treatment: A review. Water Res. 2014;50:318–340. doi: 10.1016/j.watres.2013.10.045.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2013.10.045

Citation: De Silva AO, et al. PFAS exposure pathways for humans and wildlife: a synthesis of current knowledge and key gaps in understanding. Environ. Tox. Chem. 2021;40:631–657. doi: 10.1002/etc.4935.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/etc.4935

Citation: Olsen GW, et al. Per-and polyfluoroalkyl substances (PFAS) in American Red Cross adult blood donors, 2000–2015. Environ. Res. 2017;157:87–95. doi: 10.1016/j.envres.2017.05.013.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2017.05.013

Citation: Domingo JL, Nadal M. Human exposure to per-and polyfluoroalkyl substances (PFAS) through drinking water: a review of the recent scientific literature. Environ. Res. 2019;177:108648–108648. doi: 10.1016/j.envres.2019.108648.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envres.2019.108648

Citation: Hepburn E, et al. Contamination of groundwater with per-and polyfluoroalkyl substances (PFAS) from legacy landfills in an urban re-development precinct. Environ. Poll. 2019;248:101–113. doi: 10.1016/j.envpol.2019.02.018.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2019.02.018

Citation: Bai X, Son Y. Perfluoroalkyl substances (PFAS) in surface water and sediments from two urban watersheds in Nevada, USA. Sci. Tot. Envir. 2021;751:141622–141622. doi: 10.1016/j.scitotenv.2020.141622.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.scitotenv.2020.141622

Citation: Li Y, et al. Formation and fate of perfluoroalkyl acids (PFAAs) in a laboratory-scale urban wastewater system. Water Res. 2022;216:118295–118295. doi: 10.1016/j.watres.2022.118295.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.watres.2022.118295

Citation: Hale SE, et al. Sorbent amendment as a remediation strategy to reduce PFAS mobility and leaching in a contaminated sandy soil from a Norwegian firefighting training facility. Chemosphere. 2017;171:9–18. doi: 10.1016/j.chemosphere.2016.12.057.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2016.12.057

Citation: Barber JL, et al. Analysis of per-and polyfluorinated alkyl substances in air samples from Northwest Europe. J. Environ. Monit. 2007;9:530–541. doi: 10.1039/b701417a.
Title: None
PMID: None
PMCID: None
DOI: 10.1039/b701417a

Citation: Koch A, et al. Point source characterization of per-and polyfluoroalkyl substances (PFASs) and extractable organofluorine (EOF) in freshwater and aquatic invertebrates. Environ. Sci.-Proc. Imp. 2019;21:1887–1898.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Pétré MA, et al. Per-and polyfluoroalkyl substance (PFAS) transport from groundwater to streams near a PFAS manufacturing facility in North Carolina, USA. Environ. Sci. Tech. 2021;55:5848–5856. doi: 10.1021/acs.est.0c07978.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c07978

Citation: Ahrens L, Norström K, Viktor T, Cousins AP, Josefsson S. Stockholm Arlanda Airport as a source of per-and polyfluoroalkyl substances to water, sediment and fish. Chemosphere. 2015;129:33–38. doi: 10.1016/j.chemosphere.2014.03.136.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.chemosphere.2014.03.136

Citation: Adamson DT, et al. Mass-based, field-scale demonstration of PFAS retention within AFFF-associated source areas. Environ. Sci. Tech. 2020;54:15768–15777. doi: 10.1021/acs.est.0c04472.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.est.0c04472

Citation: Quinnan J, et al. Application of PFAS‐mobile lab to support adaptive characterization and flux‐based conceptual site models at AFFF releases. Remed. J. 2021;31:7–26. doi: 10.1002/rem.21680.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/rem.21680

Citation: Schroeder T, Bond D, Foley J. PFAS soil and groundwater contamination via industrial airborne emission and land deposition in SW Vermont and Eastern New York State, USA. Environ. Sci.-Proc. Imp. 2021;23:291–301.
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Hale SE, Canivet B, Rundberget T, Langberg HA, Allan IJ. Using passive samplers to track Per and Polyfluoroalkyl Substances (PFAS) emissions from the paper industry: laboratory calibration and field verification. Front. Env. Sci. 2021;9:621–629. doi: 10.3389/fenvs.2021.796026.
Title: None
PMID: None
PMCID: None
DOI: 10.3389/fenvs.2021.796026

Citation: Hu XC, et al. Detection of poly-and perfluoroalkyl substances (PFASs) in US drinking water linked to industrial sites, military fire training areas, and wastewater treatment plants. Environ. Sci. Tech. Let. 2016;3:344–350. doi: 10.1021/acs.estlett.6b00260.
Title: None
PMID: None
PMCID: None
DOI: 10.1021/acs.estlett.6b00260

Citation: Ojha S, et al. A geospatial and binomial logistic regression model to prioritize sampling for per‐and polyfluorinated alkyl substances in public water systems. Integr. Environ. Assess. 2023;19:163–174. doi: 10.1002/ieam.4614.
Title: None
PMID: None
PMCID: None
DOI: 10.1002/ieam.4614

Citation: Ebert JC, Altman RB. Robust recognition of zinc binding sites in proteins. Protein Sci. 2008;17:54–65. doi: 10.1110/ps.073138508.
Title: None
PMID: None
PMCID: None
DOI: 10.1110/ps.073138508

Citation: Wilkinson MD, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci. Data. 2016;3:1–9. doi: 10.1038/sdata.2016.18.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/sdata.2016.18

Citation: Boeckhout M, Zielhuis GA, Bredenoord AL. The FAIR guiding principles for data stewardship: fair enough? Eur. J. Hum. Genet. 2018;26:931–936. doi: 10.1038/s41431-018-0160-0.
Title: None
PMID: None
PMCID: None
DOI: 10.1038/s41431-018-0160-0

Citation: Thompson P. T., Ojha S., Powell C. D., Pennell K. G. & Moseley H. N. B. A proposed FAIR approach for disseminating geospatial information system maps. Accepted Sci. Data (2023).
Title: None
PMID: None
PMCID: None
DOI: None

Citation: Zsóka Á, Szerényi ZM, Széchy A, Kocsis T. Greening due to environmental education? Environmental knowledge, attitudes, consumer behavior and everyday pro-environmental activities of Hungarian high school and university students. J. Clean. Prod. 2013;48:126–138. doi: 10.1016/j.jclepro.2012.11.030.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.jclepro.2012.11.030

Citation: Guelfo JL, Adamson DT. Evaluation of a national data set for insights into sources, composition, and concentrations of per-and polyfluoroalkyl substances (PFASs) in US drinking water. Environ, Poll. 2018;236:505–513. doi: 10.1016/j.envpol.2018.01.066.
Title: None
PMID: None
PMCID: None
DOI: 10.1016/j.envpol.2018.01.066

Citation: Ohja S, Thompson PT, Powell CD, Moselet HNB, Pennell KP. 2022. A FAIR approach to detect and share PFAS hot-spot areas and water systems in Kentucky. Figshare.
Title: None
PMID: None
PMCID: None
DOI: 10.6084/m9.figshare.15218958

